(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 February 2024 (15.02.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/035662 A2

(51) International Patent Classification:
C07K 16/30 (2006.01) *A61K 39/00* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2023/029676

(22) International Filing Date:
08 August 2023 (08.08.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/396,910 10 August 2022 (10.08.2022) US

(71) Applicants: **MERCK SHARP & DOHME LLC** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US). **DRAGONFLY THERAPEUTICS, INC.** [US/US]; 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US).

(72) Inventors: **BEEBE, Amy M.**; 213 E. Grand Avenue, South San Francisco, California 94080 (US). **FAYADAT-DILMAN, Laurence**; 213 E. Grand Avenue, South San Francisco, California 94080 (US). **JAUN, Veronica M.**; 213 E. Grand Avenue, South San Francisco, California 94080 (US). **CHANG, Gregory P.**; 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **CHATTOPADHYAY, Souvik**; 196 N. Main Street, Sharon, Massachusetts 02067 (US). **CHEUNG, Ann F.**; 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **GRINBERG, Asya**; 37 Follen Road, Lexington, Massachusetts 02421 (US). **HEIN, Pyae P.**; 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **WAGTMANN, Nicolai**; 1776 Monument Street, Concord, Massachusetts 01742 (US).

(74) Common Representative: **MERCK SHARP & DOHME LLC**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

WO 2024/035662 A2

(54) Title: PROTEINS BINDING NKG2D, CD16, AND CEACAM5



FIG. 1

(57) Abstract: Multi-specific binding proteins that bind NKG2D, CD16, and CEACAM5 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.

[Continued on next page]

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*